The results of the present study showed that COX-2 expression was significantly higher in CRC tissues compared to healthy colon tissues, which is consistent with the study of Negi et al. (
25). Meanwhile, the findings of other studies including Soumaoro et al. (
14), Yamauchi et al. (
26), and Xiong et al. (
27) showed that the level of COX-2 gene expression in cancer tissues was almost the same as in healthy tissues.
The exact mechanism of COX-2 overexpression at the molecular level is still unknown. However, several studies have reported that cells overexpressing COX-2 help control the process of angiogenesis and secrete inflammatory prostaglandins that inhibit apoptosis or increase invasiveness (
28,
29). Some studies have described that some COX-2 inhibitors prevent adenoma recurrence in patients with a history of primary adenoma. They have also observed that COX-2 expression is increased in colorectal adenomas and carcinomas. All these observations suggest that there is an important role for COX-2 overexpression in colorectal carcinogenesis (
12,
30,
31).
However, the role of COX-2 overexpression in understanding the biological behavior of CRC is still controversial. Since Eberhart et al. first demonstrated increased COX-2 expression in CRC (
32), several studies have since shown consistent COX-2 expression levels in CRC (
14,
26,
27). These discrepancies in results may be related to the diagnostic methods used, the patient groups, and especially to the grading system used in the studies (
33-
35).
The findings of the present study showed that Ch/Cr-NPS reduced COX-2 gene expression, which is consistent with the findings of some previous similar studies. In studies conducted by Kang et al. (
36), Chun et al. (
37) and Hong et al. (
38), it was reported that curcumin-treated cells showed reduced COX-2 expression in various cell lines by inhibiting the mitogen-activated protein kinase (MAPK) signaling pathways. Curcumin is a yellow tautomeric compound and is relatively soluble in organic solvents such as dimethyl sulfoxide, ethanol, methanol, chloroform, or acetone. Curcumin, chemically known as diferuloyl methane, is a hydrophobic polyphenol obtained from the rhizome of the turmeric plant and has a unique place in traditional therapies. The anticancer potential of curcumin stems from its ability to suppress the proliferation of a wide range of tumor cells and downregulate the transcription factors AP_1, NF_KB, and Egr_1. Curcumin inhibits protein kinase and serine/threonine protein activity by reducing the expression of NOS, LOX, COX-2, TNF, UPA, MMP9, chemokines, cell surface adhesion molecules, and cyclin D, as well as by downregulating growth factor receptors such as EGFR and HER2, and can suppress the initiation of tumor progression and metastasis (
15-
18,
22-
24). Curcumin is pharmacologically safe; however, a major obstacle is its poor aqueous solubility, which significantly limits its bioavailability and clinical efficacy in biological systems. Therefore, considering the potential therapeutic efficacy of curcumin, efforts have been made to increase its solubility and bioavailability (
39).
Chitosan, as a biopolymer with abundant resources, easy modification, and nontoxicity, can serve as an ideal carrier for the delivery of anticancer drugs. Modification of chitosan through the involvement of its amino, acetamide, and hydroxy groups can increase its solubility and exert significant anticancer activity. Chitosan and its various derivatives selectively penetrate cancer cell membranes, and its anticancer activity is mediated through various pathways, including cellular enzymatic pathways, antiangiogenic, immunomodulatory, antioxidant defense mechanisms, and apoptosis (
40-
42).